▲ Peaking
Business
🔮 holds
Fierce Pharma
Coverage by Fierce Pharma as tracked by Newsylist.
58trends covered
7broke first
58articles tracked
◼ Archived
Business
🔮 holds ✗
European drugmakers say they are ‘losing ground’ to US and Chinese rivals
◼ Archived
Health
🔮 holds ✗
Trump calls for some childhood vaccines be split into smaller doses
◼ Archived
Business
🔮 holds ✗
Why Novo Stock Is Dropping After Drugmaker Unveils Ambitious Growth Plan
◼ Archived
Business
🔮 holds ✗
EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say
◼ Archived
Business
🔮 holds ✗
FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
◼ Archived
Business
🔮 holds ✗
Vera kidney drug Trutakna shows strong final results in Phase 3 trial
◼ Archived
Business
🔮 holds ✗
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
◼ Archived
Business
🔮 holds ✗
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
◼ Archived
Business
🔮 fades ✓
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
◼ Archived
Business
🔮 holds ✗
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
◼ Archived
Business
🔮 holds ✗
FDA announces nationwide recall of epinephrine injections after reports of cracked vials
◼ Archived
Business
🔮 holds ✗
Summit Packs A Punch For Merck's Keytruda
◼ Archived
Business
🔮 holds ✗
CBER official overruled review team’s rejection of new Replimune melanoma drug
◼ Archived
Business
🔮 holds ✗
ARPA-H awards $125M for manufacturing custom RNA therapies on demand
◼ Archived
Business
🔮 holds ✗
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
◼ Archived
Business
🔮 holds ✗
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Trump’s new drug pricing deals aim to slash prescription costs, sparking a wave of coverage on potential savings.
◼ Archived
Business
🔮 fades ✓
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
◼ Archived
Business
🔮 fades ✓
US FDA approves Lilly's Mounjaro to reduce cardiovascular risk
◼ Archived
Business
🔮 holds ✗
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
◼ Archived
Business
🔮 holds ✗
The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
◼ Archived
Health
🔮 holds ✗
The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify
◼ Archived
Business
🔮 holds ✗
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg
◼ Archived
Business
🔮 fades ✓
McKesson strikes $2.25 billion Precision Medicine deal in clinical research bets
◼ Archived
Health
🔮 holds ✗
RFK Jr. may upend how vaccine recommendations are categorized
◼ Archived
Business
🔮 holds ✗
FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
◼ Archived
Business
🔮 fades ✓
Bristol Myers to build $2.3 billion manufacturing site in Houston
◼ Archived
Business
🔮 fades ✓
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
◼ Archived
Business
🔮 holds ✗
FDA approves Replimune melanoma drug previously rejected twice
◼ Archived
Business
🔮 fades ✓
The Race to Come Up With the Next Big Sleep Drug
◼ Archived
Business
🔮 fades ✓
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
◼ Archived
Business
🔮 holds ✗
Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
◼ Archived
Business
🔮 holds ✗
F.D.A. Approves Moderna’s mRNA Flu Vaccine
◼ Archived
Business
🔮 holds ✗
Novo Nordisk Stock Bounces Back After Surprise Earnings Report
◼ Archived
Business
🔮 holds ✗
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
◼ Archived
Health
🔮 holds ✗
Lipfendra vs statins: How these cholesterol-lowering drugs compare
◼ Archived
Business
🔮 fades ✓
Pfizer Covid Pill Revenue Plunges 95%. That’s Just One Reason the Stock Is Slipping.
◼ Archived
Business
🔮 holds ✗
AstraZeneca Shares Fall on Deal Talks With Bristol-Myers
◼ Archived
Business
🔮 fades ✓
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
GSK is implementing a $2.5 billion, three-year restructuring initiative to prioritize late-stage drug development and reorganize its research operations.
◼ Archived
Business
🔮 holds ✗
Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight
5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
◼ Archived
Business
🔮 holds ✗
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
The FDA has granted approval to Otsuka for Simtriyo, marking the introduction of the first triple reuptake inhibitor for the treatment of ADHD.
◼ Archived
Business
🔮 fades ✓
Earnings live: AstraZeneca stock rises to kick off a busy earnings week
AstraZeneca shares rise after Q2 2026 earnings beat driven by strong cancer drug sales.
◼ Archived
Business
🔮 holds ✗
Trump Live Updates: FDA Peptide Meetings, Tariffs and Latest News
FDA advisory committees have issued split decisions on the legal path for peptides amid high-profile advocacy for their wider availability.
◼ Archived
Business
🔮 holds ✓
FDA panel considers easing peptide restrictions
7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
◼ Archived
Business
🔮 holds ✗
Why Arrowhead Shot Sky-High, While Ionis Toppled
8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
◼ Archived
Business
🔮 holds ✓
The F.D.A. Approves a New Pill to Slash Cholesterol Levels
The FDA has approved Lipfendra, the first-of-its-kind oral PCSK9 inhibitor designed to significantly reduce cholesterol levels.
◼ Archived
Business
🔮 holds ✓
J&J Dipped On Its Report, Why Intuitive, Others Celebrated
◼ Archived
Business
🔮 holds ✗
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
◼ Archived
Business
🔮 holds ✓
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
Sanofi's Sarclisa becomes the first cancer drug approved by the FDA for delivery via an on-body injector for multiple myeloma.
◼ Archived
Business
🔮 fades ✗
AstraZeneca, Ionis report major trial failure with heart disease drug
5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
◼ Archived
Business
🔮 holds ✓
FDA approves Vera Therapeutics kidney disease treatment
The FDA has approved Vera Therapeutics' drug Trutakna to treat primary IgA nephropathy, sparking a new market competition for kidney disease treatments.
◼ Archived
Business
🔮 holds ✓
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
◼ Archived
Business
🔮 holds ✗
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
The FDA has launched a new initiative to accelerate the review process for new pharmaceutical manufacturing facilities.
◼ Archived
Business
🔮 holds ✗
Sanofi under antitrust probe as European Commission kicks off formal proceedings
Sanofi faces EU antitrust probe over flu vaccine marketing
◼ Archived
Business
🔮 fades ✓
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
European regulators are recommending the revocation of marketing authorization for Amgen's rare-disease drug Tavneos following new data.
◼ Archived
Business
🔮 holds ✗
New Drugs Are Replacing Chemo for Aggressive Breast Cancer
The FDA has granted broad first-line approval for Gilead's Trodelvy, signaling a shift away from traditional chemotherapy for aggressive breast cancer.
◼ Archived
Business
🔮 holds ✗
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
◼ Archived
Health
🔮 holds ✗